A director at Cosmo Pharmaceuticals N.V. sold 500 shares at 65.900CHF and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
3Q'25 vs. 3Q'24 Results Sales: € 374.3 M (-3.0% vs. -3.7% BS(e) and -3.0% consensus); EBITDA: € 112.8 M (+0.1% vs. -3.6% BS(e) and -3.3% consensus); Net Profit: € 57.4 M; 9M'25 vs. 9M'24 Results Sales: € 1.124 Bn (-7.6% vs. -7.8% BS(e) and -7.5% consensus); EBITDA: € 328.9 M (-2.6% vs. -3.8% BS(e) and -3.7% consensus); Net Profit: € 165.2 M;
Rdos. 3T'25 vs 3T'24: Ventas: 374,3 M euros (-3,0% vs -3,7% BS(e) y -3,0% consenso); EBITDA: 112,8 M euros (+0,1% vs -3,6% BS(e) y -3,3% consenso); BDI: 57,4 M euros. Rdos. 9meses'25 vs 9meses'24: Ventas: 1.124 M euros (-7,6% vs -7,8% BS(e) y -7,5% consenso); EBITDA: 328,9 M euros (-2,6% vs -3,8% BS(e) y -3,7% consenso); BDI: 165,2 M euros.
NEWS SUMMARY: ENAGÁS, TELEFÓNICA, VIDRALA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. IBEX looking up at 16,000 points Following the strong session in Asia (Japan hit a new record high), the euphoria continued in Europe, which rose more than +1.3% thanks to the German DAX and the IBEX. In the STOXX 600, all the se...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.